Shares of Halozyme Therapeutics (NASDAQ: HALO), a drug developer with a keen focus on creating novel therapies to treat cancer, dropped as much as 10% during Friday’s trading session following the announcement and pricing of a secondary stock offering after the closing bell on Thursday.